TY - JOUR
T1 - Péptido natriurético de tipo B e insuficiencia cardiaca aguda
T2 - homeostasis de fluidos, biomarcadores y terapéutica
AU - Torres-Courchoud, I.
AU - Chen, H. H.
N1 - Funding Information:
This research was supported by grants HL P01 HL76611 and R01HL84155 from the National Institutes of Health and Mayo Foundation awarded to Dr Horng Chen.
Publisher Copyright:
© 2016 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.
AB - Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.
KW - Brain natriuretic peptide
KW - Heart failure
KW - Natriuretic peptide
KW - Recombinant natriuretic peptides
KW - Volume homeostasis
UR - http://www.scopus.com/inward/record.url?scp=84959511118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959511118&partnerID=8YFLogxK
U2 - 10.1016/j.rce.2016.01.009
DO - 10.1016/j.rce.2016.01.009
M3 - Review article
AN - SCOPUS:84959511118
VL - 216
SP - 393
EP - 398
JO - Revista Clinica Espanola
JF - Revista Clinica Espanola
SN - 0014-2565
IS - 7
ER -